Nanocluster-antibody-drug conjugates (NADC) as an intravesical precision theranostic agent for interstitial cystitis
Combining anti-inflammatory effects from all individual components, intravesical NADC specifically homed to bladder mucosal lesions and capably alleviated inflammmation in chronic, acute, and prophylactic IC models of rats, as revealed by behavioral and pathological evaluations. Transcriptomics unveiled cytokine modulation and concomitant inhibition of perturbed IL-17, NF-kB, TNF, and JAK-STAT signaling pathways. Interestingly, the NADC reconstructed the host bladder microbiota by differentially varying anti-inflammatory and pro-inflammatory bacteria diversities.